← Back to Search
Anti-bacterial
LHP588 for Alzheimer's Disease
Bellevue, WA
Phase 2
Recruiting
Research Sponsored by Lighthouse Pharmaceuticals, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Must not have
History of cancer requiring systemic therapy in the last 5 years
History or current evidence of major neurological or psychiatric illness such as schizophrenia, bipolar disorder, Parkinson's Disease, other
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 40 - 48 weeks
Summary
"This trial aims to test a new drug, LHP588, in individuals with mild to moderate Alzheimer's disease who also have a specific bacterial infection called P. gingivalis. This infection has been
See full description
Who is the study for?
This trial is for individuals with mild to moderate Alzheimer's Disease who have experienced mental decline in the past year and tested positive for P. Gingivalis infection. Participants must be able to take a daily capsule and commit to frequent study center visits with caregiver support.Check my eligibility
What is being tested?
The study tests LHP588, aimed at targeting P. Gingivalis bacteria linked to dementia, against a placebo. The goal is to see if it can slow down Alzheimer's progression. It involves blind treatment over up to 64 weeks, including assessments like MMSE and blood tests.See study design
What are the potential side effects?
Potential side effects of LHP588 are not specified here but typically could include reactions related to the digestive system, allergies or skin reactions, headaches or dizziness due to changes in brain function.
Eligibility Criteria
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have not had cancer treatment in the last 5 years.
show original
Select...
I do not have major neurological or psychiatric illnesses like schizophrenia or Parkinson's.
show original
Select...
I haven't had recent serious heart issues.
show original
Select...
I am currently receiving treatment for dementia with specific medications.
show original
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 40 - 48 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~40 - 48 weeks
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Secondary study objectives
Change from baseline in ADCS-ADL to the end of treatment (at Week 40-48)
Change from baseline in CDR-SB to the end of treatment (at Week 40-48)
Trial Design
3Treatment groups
Experimental Treatment
Placebo Group
Group I: LHP588 50 mgExperimental Treatment1 Intervention
Group II: LHP588 25 mgExperimental Treatment1 Intervention
Group III: PlaceboPlacebo Group1 Intervention
Find a Location
Closest Location:Northwest Clinical Research Center· Bellevue, WA· 2322 miles
Who is running the clinical trial?
Lighthouse Pharmaceuticals, Inc.Lead Sponsor